Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.

As winter is knocking the door, the risk of respiratory tract infection is increasing at present scenario due to no prophylaxis of Covid-19. So, no one is safe until everyone is safe. Worldwide researchers are looking for the vaccine to remove the need for social distancing, mask-wearing and social gathering. A vaccine is like many other outcomes if the vaccine would be available; we cannot say about the effectiveness of the vaccine. Several drugs are testing to save the people life from pandemic; azithromycin is one of them. This work is a review article with the updated findings of azithromycin in the context of COVID-19. The option of azithromycin with regards to COVID-19 is justified by its anti-inflammatory, immunomodulatory, and anti-fibrotic effects and their pharmacokinetic properties, leading to effective concentrations in the target tissue. Azithromycin tends to be an effective candidate for SARS-CoV-2 replication inhibition that block the initial stage of the viral life cycle. Clinical trials at a preliminary scale and final stage show the significant results of azithromycin in supportive care therapy. Azithromycin was an early candidate for the medication of Covid-19 with or without hydroxychloroquine. It is exercised mostly as an outpatient antibiotic in COVID-19. In summing-up, any primary anti-viral and antibiotic treatment is not the only possibility of fighting COVID-19 pharmacologically. It will be an injustice with them who require broader spectrum antibiotic if we do not exercise azithromycin to them. So significant research priority is needed to determine whether azithromycin is useful in the treatment of COVID-19.